OTCPK:HALB - Post by User
Post by
averagepennieson Jan 11, 2024 8:13am
45 Views
Post# 35820970
Halberd Corporation 2023 Year-End CEO Update and 2024 Goals
Halberd Corporation 2023 Year-End CEO Update and 2024 Goals 2023 ACHIEVEMENTS
- Halberd received from the CDC two sets of antibiotic resistant bacteria and fungi (a total of 60 samples) on which to test its proprietary laser eradication methodology. Testing at Youngstown State University (YSU) successfully eradicated every sample of the various strains of E. coli, Candida auris, Shigella, and Klebsiella pneumoniae, which are linked to numerous infections, including pneumonia, meningitis, digestive tract infections, etc.
- Eradication of these bacteria was achieved by using as little as 10% of the laser power used in the initial eradication testing. The ability to achieve the same level of antigen eradication at a fraction of the power further reduces potential collateral damage to surrounding constituents in blood or CSF
- Halberd contracted Mississippi State University (MSU) to develop and conduct a preclinical testing protocol for Halberd's patent-pending nasal spray to safely counteract the effects of Traumatic Brain Injury (TBI).
- This testing at MSU demonstrated the efficacy of our nasal spray by significantly reducing key neuronal damage biomarkers by as much as 50%! The timely application of Halberd's nasal spray within hours of a traumatic brain injury may potentially mitigate factors associated with long-term neurodegeneration, often leading to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc. This product, with its capacity for more immediate application effectiveness than any other known alternative, uniquely positions Halberd to timely and effectively reduce inflammatory cytokines and excitatory neurotransmitters to avoid the irreversible damage of TBI.
- Halberd prepared and submitted seven Abstracts to the government's ARPA-H (Advance Research Projects Agency - Health) website for contract consideration. These were recommended by ARPA-H for consideration by the military, where selection decisions are pending.
- MSU collected tissue samples from the TBI mitigating nasal spray test subjects for histopathology analysis to quantify the presence of TBI biomarkers.
- Halberd signed a collaboration agreement with Athena GTX to cooperate on submissions to government agencies for the development of detection and treatment of TBI as a point-of-injury application.
- Based on the successful initial testing results of Halberd's nasal spray at MSU, Halberd requested MSU to submit a proposal to conduct an expanded sample test project to replicate the initial test with a larger sample size.
- Late in the 4th quarter, Halberd and CrodenHealth Corp. of Canada reached an agreement for CrodenHealth to produce, market, sell and distribute Halberd's patented low dose naltrexone (LDN+) products.
- During the course of the year, Halberd added to its intellectual property and now has accumulated four issued patents and 22 patents pending, indicating an extremely strong research capability.